Freddy A. Jimenez - 13 Feb 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP & GENERAL COUNSEL
Signature
/s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez
Issuer symbol
CLDX
Transactions as of
13 Feb 2024
Net transactions value
+$93,163
Form type
4
Filing time
15 Feb 2024, 16:05:55 UTC
Previous filing
20 Jun 2023
Next filing
05 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $37,563 +4,166 +237% $9.02 5,924 13 Feb 2024 Direct F1, F2
transaction CLDX Common Stock Options Exercise $55,600 +20,000 +338% $2.78* 25,924 13 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4,166 -100% $0.000000* 0 13 Feb 2024 Common Stock 4,166 $9.02 Direct F1, F3
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -20,000 -100% $0.000000* 0 13 Feb 2024 Common Stock 20,000 $2.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F2 Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F3 As of June 13, 2022, the option is fully vested.
F4 As of June 19, 2023, the option is fully vested.